Compare MGM Resorts International (MGM) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Neurocrine Biosciences Inc — how do they compare? MGM Resorts International trades at $43.82 (market cap $11.10B), while Neurocrine Biosciences Inc trades at $158.43 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and MGM Resorts International pays a 0.03% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MGM | NBIX | |
|---|---|---|
Market Cap | $11.10B | $16.46B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $185.50 |
52-Week Low | $30.72 | $123.10 |
Enterprise Value | $38.40B | $16.48B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $43.36, down 2.5% with bearish technical signals despite mixed earnings performance. The company reported record Q2 2026 revenue of $17.54B but missed EPS estimates, while analyst consensus remains divided with a $51.14 price target. Recent news highlights ongoing acquisition investigations and BetMGM's expansion in Canadian markets.
MGM faces near-term pressure from earnings volatility and acquisition uncertainty, but maintains strong revenue growth and digital expansion. Key risks include regulatory scrutiny and competitive pressures, while institutional sentiment leans neutral with balanced buy/hold ratings suggesting cautious optimism for recovery.
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
